NHS or private — where ChondroFiller sits

ChondroFiller is not available on the NHS. There is no NICE technology appraisal for this injectable collagen scaffold as of mid-2026, no commissioning pathway through any devolved health service, and no GP referral route that leads to this product. A GP may write a supporting letter for a private consultation, but that letter does not unlock NHS funding.

The NHS funds only one cartilage cell therapy for knee defects: autologous chondrocyte implantation (ACI), a position that has not changed since 2017. Injectable off-the-shelf scaffolds such as ChondroFiller sit entirely outside that commissioning boundary — they are categorised as Class III medical devices rather than cell therapies, and no appraisal process to bring them within NHS provision has been initiated.

For patients, this means treatment is either self-funded or accessed through private health insurance with written pre-authorisation obtained before the appointment. Planning accordingly — rather than expecting an NHS route to open — is the practical starting point for anyone researching ChondroFiller.

How defect size determines your price tier

Pricing for ChondroFiller injection follows a straightforward clinical logic: the extent of cartilage damage determines how many units of scaffold are required, and the number of units determines the guide cost. Three tiers exist.

• One box (approx. 3 cm²): guide cost £3,000
• Two boxes (approx. 4.5 cm²): guide cost £5,500
• Three boxes (approx. 6 cm²): guide cost £8,000

Complex or severe Grade III/IV defects may attract a guide cost of approximately £9,800.

The critical point for planning purposes is that defect extent cannot be confirmed without imaging review at clinical assessment. Patients cannot self-select a tier in advance — the size of the affected area must be measured before the appropriate volume of scaffold can be determined. Until that assessment takes place, the realistic planning window is the full £3,000–£9,800 range.

The smaller the area of cartilage damage, the lower the tier; but smaller does not always mean straightforward, and severity grading at assessment may shift the final figure.

This tier structure applies consistently across all joints that can be treated via this pathway: knee, hip, ankle, shoulder, elbow, and wrist. No additional charge is applied for treating a particular joint type — the guide cost is driven by defect size, not anatomical location.

What the guide cost actually covers

One practical advantage of the bundled pricing model is that the guide cost quoted at assessment is the full cost — there are no follow-on invoices for individual components. The quote covers the pre-injection consultation, imaging review, real-time ultrasound guidance, the ChondroFiller product itself, intravenous antibiotic cover administered during the appointment, and a six-week follow-up. This stands in contrast to standard UK private musculoskeletal care, which typically generates separate bills for consultation, imaging, anaesthesia, and any consumables used.

The treatment itself is delivered as an ultrasound-guided outpatient injection under local anaesthesia — a clinic appointment, not a hospital admission. A typical session lasts approximately 30 to 45 minutes. There is no theatre booking, no general anaesthetic, and no surgical incision; patients are assessed, treated, and discharged on the same day.

ChondroFiller is a CE-marked Class III acellular collagen scaffold — the product cost is absorbed within the bundle rather than itemised separately. Once injected, the scaffold undergoes a process called acellular matrix-induced chondrogenesis, in which it provides a structural framework that supports the body's own repair processes; the patient's progenitor cells are recruited to the site rather than introduced externally.

For anyone building a cost plan before assessment, the key point is that the guide cost is genuinely the ceiling for the standard treatment episode, not a base figure to which extras will be added.

Private insurance — what to check before booking

Private health insurance can contribute to the cost of ChondroFiller injection, though coverage is neither automatic nor consistent across policies. Approaching an insurer with the right information early is the most reliable way to find out where a particular policy stands.

Clinics bill the procedure using CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500, both of which appear on the fee schedules of several UK insurers. Approvals have been reported in clinical practice with Bupa, Aviva, and WPA — but these are examples, not a confirmed approved list, and outcomes vary from policy to policy depending on individual terms and the clinical justification provided.

Two steps are worth taking before booking:

• Request the CCSD codes from the assessing clinic. These should accompany any pre-authorisation submission so the insurer can match the procedure to its schedule.
• Submit a written pre-authorisation request before treatment begins. Claims submitted after the procedure are typically declined. A clinical summary from the assessing specialist, setting out the defect size and treatment rationale, strengthens the submission.

Insurers may approve the full guide cost, cover only part of it, or decline entirely. There is no published approval-rate data, so pre-authorisation — not assumption — is the only reliable starting point.

Where ChondroFiller sits in the UK cartilage treatment cost range

Within the broader UK cartilage regeneration market, ChondroFiller guide costs sit toward the accessible end of the spectrum. Surgical approaches range from approximately £4,000 for microfracture to around £28,000 for single-stage implantation procedures — placing ChondroFiller's £3,000–£9,800 range well below the upper tier of what cartilage care can cost. That said, it carries a meaningful premium over standard hyaluronic acid viscosupplementation or corticosteroid injections, and that premium reflects the nature of the product itself: as a CE-marked Class III medical device manufactured to pharmaceutical-grade standards and imported under prescription, it is regulated at a different level from conventional injection fluids.

Two combination pathways extend the guide costs further. ChondroFiller with Arthrosamid — a separate polyacrylamide hydrogel — carries a combined guide cost of approximately £6,000. The Tri-Active pathway, which adds autologous mesenchymal stem cells, is approximately £11,000. The distinction between what each component does matters here: Arthrosamid functions as a cushioning hydrogel within the joint space, whereas ChondroFiller is a collagen scaffold that supports acellular matrix-induced chondrogenesis. The mechanisms are distinct and complementary — not the same process applied twice.

Comparative pricing across UK providers is difficult to establish because few clinics publish full cost breakdowns for ChondroFiller injection. Patients consulting more than one specialist are advised to request an itemised guide cost from each, including what is and is not covered, so that any comparison is made on genuinely equivalent terms.

Questions to ask when choosing a ChondroFiller specialist

Before committing to a clinic, four questions are worth raising with any prospective specialist:

• How many ChondroFiller injections do you perform each year? Outcomes are technique-sensitive, and familiarity with ultrasound-guided scaffold placement is a material consideration — not merely a credential to note.
• Is the quoted cost all-inclusive? The bundled model described in this article is not universal. Confirm whether imaging, the follow-up appointment, and the product itself are covered, or whether any component is billed separately.
• Can you supply the billing codes needed for insurance pre-authorisation? A clinic with established experience of this pathway should provide them without difficulty.
• How is defect size confirmed at assessment, and what happens if it falls outside the expected tier? Understanding the imaging protocol — and whether a larger or smaller defect than anticipated would alter the plan — removes uncertainty from the pricing conversation before it becomes a problem.

The most reliable sequence is to secure a clinical assessment first, establish the correct tier before approaching an insurer, and compare any alternative quotes on equivalent components. Search MSK lists specialists who offer ChondroFiller injection across the UK; filtering by region and specialty is a practical way to identify one suited to your location and clinical situation.